NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL MEASURES THAN SUCH MEASURES UNDER SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

aXichem AB (publ) ("aXichem" or the "Company") today announces the preliminary outcome of the fully guaranteed rights issue of shares and warrants ("Units") that was announced on February 3, 2026, and whose subscription period ended today, February 27, 2026 (the "Rights Issue"). The preliminary outcome indicates that 5,811,108 Units, corresponding to approximately 69 percent of the Rights Issue, were subscribed for with unit rights. In addition, 942,213 Units were subscribed for without the support of unit rights, corresponding to approximately 11 percent of the Rights Issue. 1,691,665 Units will be subscribed for in accordance with the guarantee commitments entered into, corresponding to approximately 20 percent of the Rights Issue. In total, 8,444,986 Units will be subscribed for, corresponding to 100 percent of the Rights Issue. Through the Rights Issue, aXichem will receive approximately SEK 11 million before issue costs.

Preliminary outcome

The Rights Issue comprised a maximum of 8,444,986 Units. 5,811,108 Units, corresponding to approximately 69 percent of the Rights Issue, were subscribed for with the support of unit rights. In addition, applications have been received to subscribe for 942,213 Units without the support of unit rights, corresponding to approximately 11 percent of the Rights Issue. 1,691,665 Units will be subscribed for in accordance with the guarantee commitments entered into, corresponding to approximately 20 percent of the Rights Issue. The Rights Issue will be subscribed to 100 percent and aXichem will receive approximately SEK 11 million before issue costs.

Notification of allocation

Those who have subscribed for Units without the exercise of unit rights will be allotted Units in accordance with the principles set out in the information memorandum prepared in connection with the Rights Issue and published by the Company on 13 February 2026. Notification of allotment to the persons who have subscribed for Units without unit rights is expected to be distributed on or about 2 March 2026. Subscribed and allotted Units shall be paid in cash in accordance with the instructions on the settlement note. Investors who have subscribed through a nominee will receive notification of allotment in accordance with their respective nominee's procedures. Only those who have been assigned Units will be notified.

Final outcome and trading in BTU

The final outcome of the Rights Issue is expected to be published on or about March 2, 2026. Trading in BTU (paid subscribed Unit) is currently conducted on Nasdaq First North Growth Market and will be terminated when the Rights Issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place around week 11, 2026. BTU will then be converted into shares and warrants of series TO2A.

Financial advisors, legal advisors and issuing agents

Västra Hamnen Corporate Finance AB is acting as financial advisor and Advokatfirman Lindahl is acting as legal advisor to aXichem in connection with the Rights Issue. Nordic Issuing acts as issuing agent.

For more information:

Torsten Helsing,

VD, aXichem AB, phone: +46 706 86 33 55

E-post: [email protected]

or visit: www.axichem.com

The certified adviser for aXichem is Västra Hamnen Corporate Finance AB.

The information was submitted for publication, through the agency of the contact person set out above, on 27 February 2026 at 18:00 CET.

About aXichem 

aXichem develops, patents and markets natural analogue industrial chemicals, i.e. synthetically produced substances that have similar and comparable properties as natural substances. The Company's first product is phenylcapsaicin, which the Company commercializes under two brand names, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in poultry feed, such as chicken and turkey; as an ingredient in dietary supplements for gut health, weight management, and sports and exercise; as well as as an ingredient in dietary supplements for bioavailability enhancement of curcumin and melatonin.

aXichem is listed on Nasdaq First North Growth Market. For more information, see www.axichem.com

Important information

The publication, publication or distribution of this press release may be restricted in certain jurisdictions. Recipients of this press release in the jurisdictions in which this press release has been published, published or distributed should inform themselves about and comply with such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to acquire or subscribe for any securities in the Company in any jurisdiction.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 and Directive 2003/71/EC (together with the relevant implementations and delegated regulations, the "Prospectus Regulation") and no prospectus will be prepared in connection with the Offering. Invitations to the persons concerned to subscribe for units in the Company will only be made through the information document that the Company will publish prior to the subscription period.

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or any other securities regulatory authority in any state or other jurisdiction of the United States, and may not be offered or sold in the United States (as defined in Regulation S under the Securities Act) except for the applicable exemption from:  or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with applicable securities laws. Neither this document nor any information contained herein constitutes or forms part of an offer to sell or the solicitation of an offer to buy any securities in the United States. There will be no securities offered to the public in the United States.

In the United Kingdom, this press release is only directed at persons who are 'qualified investors' within the meaning of the UK Prospectus Regulation and who (i) have professional experience in matters relating to investments under Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (ii) are persons falling within Article 49(2)(A) to (D) of the Order;  or (iii) to whom it may otherwise lawfully be communicated. For these purposes, the term 'UK Prospectus Regulation' means Regulation EU 2017/1129 which forms part of the domestic law of the United Kingdom in accordance with domestic law, the European (Withdrawal) Act 2018.

Within the European Economic Area ("EEA"), no offer of shares or other securities is being made to the public in any country other than Sweden. In other member states of the European Union ("EU"), such an offer can only be made in accordance with exemptions in the Prospectus Regulation.

This press release may contain certain forward-looking statements that reflect the Company's current view of future events and financial and operational developments. Words such as "intends", "estimates", "expects", "may", "plans", "estimates" and other expressions that imply indications or predictions regarding future developments or trends, and are not based on historical facts, constitute forward-looking statements. Forward-looking statements are by their nature subject to both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or development and actual results may differ materially from those expressed in forward-looking statements.